GlobeNewswire Inc | Aug 4, 2020 07:00AM EDT

August 04, 2020

WOBURN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL) a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences.

BTIG Virtual Biotechnology Conference 2020Date: Monday, August 10, 2020Presentation Time: 10:30 am ET

2020 Wedbush PacGrow Healthcare Virtual ConferenceDate: Tuesday, August 11, 2020Presentation Time: 9:45 am ET

A simultaneous webcast of the presentation from the 2020 Wedbush PacGrow Healthcare Virtual Conference will be available in the Investors section of Replimunes website at www.replimune.com. A replay will be available for approximately 90 days following the conference.

About Replimune

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimunes Immulytic platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action.For more information, please visit www.replimune.com.

Investor Inquiries Chris BrinzeyWestwicke, an ICR Company339.970.2843chris.brinzey@westwicke.com

Media InquiriesArleen Goldenberg Verge Scientific Communications917.548.1582agoldenberg@vergescientific.com